Mirabaud & Cie SA Sells 320 Shares of Stryker Co. (NYSE:SYK)

Mirabaud & Cie SA lessened its position in shares of Stryker Co. (NYSE:SYK) by 4.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,490 shares of the medical technology company’s stock after selling 320 shares during the period. Stryker makes up about 0.7% of Mirabaud & Cie SA’s holdings, making the stock its 28th biggest position. Mirabaud & Cie SA’s holdings in Stryker were worth $2,337,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of SYK. Parnassus Investments LLC bought a new position in shares of Stryker in the third quarter worth approximately $762,798,000. International Assets Investment Management LLC grew its stake in Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock worth $308,433,000 after buying an additional 852,496 shares in the last quarter. RTW Investments LP bought a new position in shares of Stryker in the 3rd quarter worth $143,392,000. State Street Corp lifted its holdings in shares of Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after acquiring an additional 316,404 shares during the last quarter. Finally, FMR LLC grew its position in Stryker by 3.0% in the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after acquiring an additional 215,782 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Stryker Stock Up 3.2 %

Shares of NYSE:SYK opened at $395.86 on Wednesday. The firm has a market capitalization of $150.91 billion, a P/E ratio of 42.43, a P/E/G ratio of 2.63 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a 50 day moving average price of $375.61 and a 200-day moving average price of $359.53. Stryker Co. has a 52-week low of $307.23 and a 52-week high of $398.20.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the prior year, the company earned $2.46 earnings per share. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Tuesday, December 31st. Stryker’s payout ratio is currently 36.01%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Tuesday, January 7th. Evercore ISI boosted their price objective on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Barclays lifted their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $420.00 price objective (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.